Patient-controlled Analgesia Pumps Market Size & Share, By Drug Type (Opioid-Based PCA Pumps, Non-Opioid PCA Pumps); Product Type; Modality; End user; Application; Connectivity - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Patient-controlled Analgesia Pumps Market - Regional Analysis

North America Market Insights

North America in the market is projected to hold a share of 42.3% by the end of 2034. The market’s growth in the region is propelled by an increase in surgical volumes, the opioid crisis driving the need for controlled dosage, and smart pump integration. In addition, a surge in home healthcare services and the existence of Medicare and Medicaid coverage are also driving the market in the overall region. As per the June 2024 Annals of Thoracic Surgery organizational report, 271.5 cardiac-based surgical volumes have been conducted in the U.S., along with 55.2 valve-based surgeries. Additionally, the CABG volume was 64.5, thereby determining the increased demand for PCA pumps in the region to administer post-operative pain for patients.

The patient-controlled analgesia pumps market in the U.S. is significantly growing, owing to administrative support, an increase in healthcare expenditure, and Medicare reimbursement facilities. As per an article published by the AMA in April 2025, the healthcare expenditure in the country increased by 7.5% as of 2023 to USD 4.9 trillion. This growth rate is effectively higher than the 4.6% surge as of 2022, and this escalation is highly attributed to an upsurge in the utilization of healthcare services, along with the 92.5% insured share provision. Besides, the November 2023 NLM article demonstrated that 25% of Part B spending is covered by beneficiary premiums, with an increase in the expense for seniors.

The market in Canada is also growing, which is fueled by universal healthcare coverage, as well as government initiatives. For instance, according to the November 2022 Health Canada report, the country’s government declared a funding of USD 5 million to augment support for patients affected with chronic pain and enhance the Pain Canada network. In addition, the federal government made an investment of more than USD 184 million for pain-based research through Institutes of Health Research, and vigorously supported 17 pain-specific projects, with a valuation of more than USD 22.5 million through Health Canada’s SUAP. Therefore, this denotes a huge opportunity for the market to expand in the country, and cater to patients suffering from any form of pain.

Healthcare Spending Comparison Between the U.S. and Canada

Sources: Ross University, May 2021; World Bank Group, 2025

APAC Market Insights

Asia Pacific in the patient-controlled analgesia pumps market is expected to emerge as the fastest-growing region, with a share of 22.1% during the forecast period. The market’s development in the region is highly attributed to modernization in healthcare, aging population, and a rise in surgical conduction. In this regard, as per an article published by the NLM in August 2024, the development of strong health systems is driven by an increase in out-of-pocket (OOP) payments, ranging from 44% to 73%, particularly in South Asia, with Sri Lanka comprising the lowest at 44%. Besides, the region is subject to an increase in the non-communicable diseases (NCDs) burden, modifiable risk factor levels, and high mortality, ranging between 66% to 83%, thus suitable for the market’s exposure.

The market in China is gaining increasing traction due to an increase in the patient pool and the presence of administrative bodies to approve healthcare products and services. According to a report published by the International Trade Administration in April 2023, the comprised 36,570 hospitals, which provided more than 7.4 million beds and achieved 3.88 billion patient visits. Of all these, public facilities offered 70.2% of hospital beds received 84.2% of patient visits. Besides, the medical device market in the country is expected to gradually increase at a growth rate of 8.3%, which denotes a huge opportunity for the market’s flourishment.

The patient-controlled analgesia pumps market in India is also growing, which is driven by expansion in administrative beneficiaries. According to the August 2025 Ministry of Health and Family Welfare report, 4.5 crore (45 million) families are to benefit, with 6 crore (60 million) senior citizens with 5 Lakh rupees (approximately USD 5,715) free health insurance cover on a family basis. Therefore, based on this approval, senior citizens of more than 70 years of age are eligible to receive the AB PM-JAY benefit. Hence, with such provisions from the regional government, there is a huge opportunity for the market to gain increased exposure in the country.

Europe Market Insights

Europe in the patient-controlled analgesia pumps market is expected to garner a considerable share of 28.4% by the end of the projected timeline. The market’s development in the region is highly attributed to digital health strategies, an increase in aging demographics, and stringent pain management protocols. Besides, healthcare systems in the region have effectively focused on quality and affordability for both patients and the overall society. Additionally, advancements in PCA pumps, initiatives undertaken by government subsidies, telemedicine-integrated PCA pumps, along with opioid-sparing protocols, are other factors that are deliberately driving the market demand in the overall region.

The market in Germany is gaining increased exposure, owing to the existence of rigorous pain management standards. According to a report published by the NLM in January 2024, commonly utilized non-opioid medications for pain management in the country’s hospitals include metamizole, accounting for 98% of the management, which is followed by ibuprofen with 81.6%, paracetamol with 56.5%, diclofenac with 55.1%, coxibe with 51.7%, and ASS with 16.3%. Besides, the most common medication for opioid-based pain management in the country is hydropmorphon, constituting 98.6% of the management, thus increasing the patient-controlled analgesia pumps market’s demand.

The market in the UK is steadily growing due to the presence of NHS policies and surgical backlog clearance. In this regard, suitable explanations should be provided to patients regarding the nursing staff before undertaking any surgical procedure that includes the use of PCA pumps. According to the April 2025 Royal Cornwall Hospital report, there is an exception for clear IV fluids, including 0.9% of sodium chloride, while administering PCA pumps through a separate cannula. Therefore, with the presence of such policies, the market is expected to effectively grow in the country.

Europe’s Healthcare Expenditure Breakdown as of 2022

Source: Eurostat, November 2024